Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 4/9/19 → 9/23/20 |
Funding
- Medpace Clinical Research LLC (Prot #2125-MEL-301 // Prot #2125-MEL-301)
- Idera Pharmaceuticals, Inc. (Prot #2125-MEL-301 // Prot #2125-MEL-301)
Prot #2125-MEL-301: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma
- Chandra, Sunandana (PD/PI)
Project: Research project